Walter Wenninger
Direttore/Membro del Consiglio presso NOXXON Pharma AG
Relazioni attive
| Nome | Sesso | Età | Società collegate | Collaborazione |
|---|---|---|---|---|
| Joseph deBethizy | M | 74 |
Roche Innovation Center Copenhagen A/S
 Roche Innovation Center Copenhagen A/S Pharmaceuticals: MajorHealth Technology Roche Innovation Center Copenhagen A/S discovers and develops drugs for the treatment of oncology, metabolic diseases, and infectious diseases. The firm manufactures a pipeline of drug candidates that act selectively on disease-related ribonucleic acid to provide patients with novel treatments for both rare and common diseases. It produces pre-clinical and clinical assets for the treatment of a range of diseases including oncology, metabolic diseases, and infectious diseases. The company was founded by Matts Lundwall and Mikael Ørum on January 1, 1998 and is headquartered in Horsholm, Denmark.
NOXXON Pharma AG
 NOXXON Pharma AG BiotechnologyHealth Technology NOXXON Pharma AG operates a clinical stage biotechnology company. Its core focus is on cancer treatment. The firm offers effectiveness of cancer treatments including immuno-oncology approaches such as immune checkpoint inhibition and current standards of care such as chemotherapy and radiotherapy. The company was founded in 1997 by Sven Klussmann, Jens-Peter Fürste and Thomas Klein and is headquartered in Berlin, Germany. | 1 anni |
| Aram Andrew Mangasarian | M | 54 |
NOXXON Pharma AG
NOXXON Pharma AG BiotechnologyHealth Technology NOXXON Pharma AG operates a clinical stage biotechnology company. Its core focus is on cancer treatment. The firm offers effectiveness of cancer treatments including immuno-oncology approaches such as immune checkpoint inhibition and current standards of care such as chemotherapy and radiotherapy. The company was founded in 1997 by Sven Klussmann, Jens-Peter Fürste and Thomas Klein and is headquartered in Berlin, Germany. | 14 anni |
| Iris Löw-Friedrich | M | 63 | 10 anni | |
| Sven Klussmann | M | - |
NOXXON Pharma AG
NOXXON Pharma AG BiotechnologyHealth Technology NOXXON Pharma AG operates a clinical stage biotechnology company. Its core focus is on cancer treatment. The firm offers effectiveness of cancer treatments including immuno-oncology approaches such as immune checkpoint inhibition and current standards of care such as chemotherapy and radiotherapy. The company was founded in 1997 by Sven Klussmann, Jens-Peter Fürste and Thomas Klein and is headquartered in Berlin, Germany. | 27 anni |
| Craig Johnstone | M | 54 | 12 anni | |
| Josef Puchta | M | 70 |
German Cancer Research Center
 German Cancer Research Center Hospital/Nursing ManagementHealth Services German Cancer Research Center offers biomedical research services. It develops novel approaches to make tumor diagnosis more precise and for a treatment of cancer. The firm provides different research programs such as cell and tumor biology, functional and structural genomics, risk factors and prevention, tumor immunology, imaging and radio oncology, and translational cancer research. The company was founded in 1964 and is headquartered in Heidelberg, Germany. | 28 anni |
| Bertram Köhler | M | 53 |
NOXXON Pharma AG
NOXXON Pharma AG BiotechnologyHealth Technology NOXXON Pharma AG operates a clinical stage biotechnology company. Its core focus is on cancer treatment. The firm offers effectiveness of cancer treatments including immuno-oncology approaches such as immune checkpoint inhibition and current standards of care such as chemotherapy and radiotherapy. The company was founded in 1997 by Sven Klussmann, Jens-Peter Fürste and Thomas Klein and is headquartered in Berlin, Germany. | - |
| Denis Lucquin | M | 67 |
NOXXON Pharma AG
NOXXON Pharma AG BiotechnologyHealth Technology NOXXON Pharma AG operates a clinical stage biotechnology company. Its core focus is on cancer treatment. The firm offers effectiveness of cancer treatments including immuno-oncology approaches such as immune checkpoint inhibition and current standards of care such as chemotherapy and radiotherapy. The company was founded in 1997 by Sven Klussmann, Jens-Peter Fürste and Thomas Klein and is headquartered in Berlin, Germany. | - |
| Cord Dohrmann | M | 60 | 14 anni | |
| Peter Johann | M | 67 |
NOXXON Pharma AG
NOXXON Pharma AG BiotechnologyHealth Technology NOXXON Pharma AG operates a clinical stage biotechnology company. Its core focus is on cancer treatment. The firm offers effectiveness of cancer treatments including immuno-oncology approaches such as immune checkpoint inhibition and current standards of care such as chemotherapy and radiotherapy. The company was founded in 1997 by Sven Klussmann, Jens-Peter Fürste and Thomas Klein and is headquartered in Berlin, Germany. | - |
| Hubert Birner | M | 57 |
NOXXON Pharma AG
NOXXON Pharma AG BiotechnologyHealth Technology NOXXON Pharma AG operates a clinical stage biotechnology company. Its core focus is on cancer treatment. The firm offers effectiveness of cancer treatments including immuno-oncology approaches such as immune checkpoint inhibition and current standards of care such as chemotherapy and radiotherapy. The company was founded in 1997 by Sven Klussmann, Jens-Peter Fürste and Thomas Klein and is headquartered in Berlin, Germany. | - |
| Olivier Litzka | M | 56 |
NOXXON Pharma AG
NOXXON Pharma AG BiotechnologyHealth Technology NOXXON Pharma AG operates a clinical stage biotechnology company. Its core focus is on cancer treatment. The firm offers effectiveness of cancer treatments including immuno-oncology approaches such as immune checkpoint inhibition and current standards of care such as chemotherapy and radiotherapy. The company was founded in 1997 by Sven Klussmann, Jens-Peter Fürste and Thomas Klein and is headquartered in Berlin, Germany. | - |
| Jarl Ulf Birger Jungnelius | M | 73 |
NOXXON Pharma AG
NOXXON Pharma AG BiotechnologyHealth Technology NOXXON Pharma AG operates a clinical stage biotechnology company. Its core focus is on cancer treatment. The firm offers effectiveness of cancer treatments including immuno-oncology approaches such as immune checkpoint inhibition and current standards of care such as chemotherapy and radiotherapy. The company was founded in 1997 by Sven Klussmann, Jens-Peter Fürste and Thomas Klein and is headquartered in Berlin, Germany. | 7 anni |
| Heike Hausfeld | F | 58 | 30 anni | |
| Elaine Sullivan | M | 63 | 9 anni |
Grafico relazionale
Relazione in diverse aziende
Relazioni precedenti
| Nome | Sesso | Età | Società collegate | Collaborazione |
|---|---|---|---|---|
| Claus Tycho Bræstrup | M | 79 |
Roche Innovation Center Copenhagen A/S
Roche Innovation Center Copenhagen A/S Pharmaceuticals: MajorHealth Technology Roche Innovation Center Copenhagen A/S discovers and develops drugs for the treatment of oncology, metabolic diseases, and infectious diseases. The firm manufactures a pipeline of drug candidates that act selectively on disease-related ribonucleic acid to provide patients with novel treatments for both rare and common diseases. It produces pre-clinical and clinical assets for the treatment of a range of diseases including oncology, metabolic diseases, and infectious diseases. The company was founded by Matts Lundwall and Mikael Ørum on January 1, 1998 and is headquartered in Horsholm, Denmark. | - |
| Keith Graham McCullagh | M | 80 |
Roche Innovation Center Copenhagen A/S
Roche Innovation Center Copenhagen A/S Pharmaceuticals: MajorHealth Technology Roche Innovation Center Copenhagen A/S discovers and develops drugs for the treatment of oncology, metabolic diseases, and infectious diseases. The firm manufactures a pipeline of drug candidates that act selectively on disease-related ribonucleic acid to provide patients with novel treatments for both rare and common diseases. It produces pre-clinical and clinical assets for the treatment of a range of diseases including oncology, metabolic diseases, and infectious diseases. The company was founded by Matts Lundwall and Mikael Ørum on January 1, 1998 and is headquartered in Horsholm, Denmark. | 5 anni |
| Paul Herrling | M | 78 | 3 anni | |
| Karl-Ludwig Kley | M | 73 | 16 anni | |
| Bernd Hirsch | M | 53 | - | |
| Bernd Metzner | M | 53 | 4 anni | |
| Wolfgang Plischke | M | 72 | 7 anni | |
| Andreas Pinkwart | M | 64 | 3 anni | |
| Wilhelm Stahl | M | 64 | - | |
| Lars Benecke | M | - | - | |
| Neil Gibson | M | 67 | 4 anni | |
| David Roblin | M | 57 | 2 anni | |
| Holger Zimmermann | M | - | 6 anni | |
| Helga Rübsamen-Schaeff | M | 75 | 12 anni | |
| Hanne Damgaard Jensen | F | - |
Roche Innovation Center Copenhagen A/S
Roche Innovation Center Copenhagen A/S Pharmaceuticals: MajorHealth Technology Roche Innovation Center Copenhagen A/S discovers and develops drugs for the treatment of oncology, metabolic diseases, and infectious diseases. The firm manufactures a pipeline of drug candidates that act selectively on disease-related ribonucleic acid to provide patients with novel treatments for both rare and common diseases. It produces pre-clinical and clinical assets for the treatment of a range of diseases including oncology, metabolic diseases, and infectious diseases. The company was founded by Matts Lundwall and Mikael Ørum on January 1, 1998 and is headquartered in Horsholm, Denmark. | 1 anni |
| Joachim Bender | M | 69 | 15 anni | |
| Paul Grant Higham | M | - | 11 anni | |
| Stefan Hesse | M | - | - | |
| Katharina Jansen | M | - | 22 anni | |
| Claus Asbjørn Andersson | M | 56 |
Roche Innovation Center Copenhagen A/S
Roche Innovation Center Copenhagen A/S Pharmaceuticals: MajorHealth Technology Roche Innovation Center Copenhagen A/S discovers and develops drugs for the treatment of oncology, metabolic diseases, and infectious diseases. The firm manufactures a pipeline of drug candidates that act selectively on disease-related ribonucleic acid to provide patients with novel treatments for both rare and common diseases. It produces pre-clinical and clinical assets for the treatment of a range of diseases including oncology, metabolic diseases, and infectious diseases. The company was founded by Matts Lundwall and Mikael Ørum on January 1, 1998 and is headquartered in Horsholm, Denmark. | 4 anni |
| Hans-Peter Schaefer | M | 73 | 14 anni | |
| Peter Vanacker | M | 58 | 4 anni | |
| Dariusz Adam Bak | M | 55 | 4 anni | |
| Jonathan Freve | M | 46 |
Roche Innovation Center Copenhagen A/S
Roche Innovation Center Copenhagen A/S Pharmaceuticals: MajorHealth Technology Roche Innovation Center Copenhagen A/S discovers and develops drugs for the treatment of oncology, metabolic diseases, and infectious diseases. The firm manufactures a pipeline of drug candidates that act selectively on disease-related ribonucleic acid to provide patients with novel treatments for both rare and common diseases. It produces pre-clinical and clinical assets for the treatment of a range of diseases including oncology, metabolic diseases, and infectious diseases. The company was founded by Matts Lundwall and Mikael Ørum on January 1, 1998 and is headquartered in Horsholm, Denmark. | - |
| Habib Dable | M | 54 | 22 anni | |
| Manuela Strauch | F | 52 | - | |
| Tomas Kahn | M | 73 |
German Cancer Research Center
German Cancer Research Center Hospital/Nursing ManagementHealth Services German Cancer Research Center offers biomedical research services. It develops novel approaches to make tumor diagnosis more precise and for a treatment of cancer. The firm provides different research programs such as cell and tumor biology, functional and structural genomics, risk factors and prevention, tumor immunology, imaging and radio oncology, and translational cancer research. The company was founded in 1964 and is headquartered in Heidelberg, Germany. | 13 anni |
| Rick Ryan | M | - | 14 anni | |
| Rolf Hoffmann | M | 48 | - | |
| Cony D’Cruz | M | 62 | 9 anni | |
| Duane Tucker | M | - | 2 anni | |
| William Carson | M | 76 | 8 anni | |
| Søren Tulstrup | M | 59 |
Roche Innovation Center Copenhagen A/S
Roche Innovation Center Copenhagen A/S Pharmaceuticals: MajorHealth Technology Roche Innovation Center Copenhagen A/S discovers and develops drugs for the treatment of oncology, metabolic diseases, and infectious diseases. The firm manufactures a pipeline of drug candidates that act selectively on disease-related ribonucleic acid to provide patients with novel treatments for both rare and common diseases. It produces pre-clinical and clinical assets for the treatment of a range of diseases including oncology, metabolic diseases, and infectious diseases. The company was founded by Matts Lundwall and Mikael Ørum on January 1, 1998 and is headquartered in Horsholm, Denmark. | 4 anni |
| Heino von Prondzynski | M | 73 | 20 anni | |
| Henning Walczak | M | - |
German Cancer Research Center
German Cancer Research Center Hospital/Nursing ManagementHealth Services German Cancer Research Center offers biomedical research services. It develops novel approaches to make tumor diagnosis more precise and for a treatment of cancer. The firm provides different research programs such as cell and tumor biology, functional and structural genomics, risk factors and prevention, tumor immunology, imaging and radio oncology, and translational cancer research. The company was founded in 1964 and is headquartered in Heidelberg, Germany. | - |
| Corey Goodman | M | 72 | 2 anni | |
| Martinus Adrianus van Osch | M | - |
Roche Innovation Center Copenhagen A/S
Roche Innovation Center Copenhagen A/S Pharmaceuticals: MajorHealth Technology Roche Innovation Center Copenhagen A/S discovers and develops drugs for the treatment of oncology, metabolic diseases, and infectious diseases. The firm manufactures a pipeline of drug candidates that act selectively on disease-related ribonucleic acid to provide patients with novel treatments for both rare and common diseases. It produces pre-clinical and clinical assets for the treatment of a range of diseases including oncology, metabolic diseases, and infectious diseases. The company was founded by Matts Lundwall and Mikael Ørum on January 1, 1998 and is headquartered in Horsholm, Denmark. | - |
| Caren Mason | F | 70 | 7 anni | |
| David A. Lowe | M | 77 | 5 anni | |
| Frank Armstrong | M | 67 | 3 anni | |
| Vikas Sinha | M | 60 | 11 anni | |
| Stephen W. Zaruby | M | 61 | 6 anni | |
| Bernhard Opitz | M | 66 | 20 anni | |
| Albert P. L. Stroucken | M | 76 | 1 anni | |
| Charles W. Wolcott | M | 71 | 7 anni | |
| Roland Oetker | M | 75 | 3 anni | |
| Ernst-Ludwig Winnacker | M | 82 | 19 anni | |
| Hoa Hong | F | - | 4 anni | |
| Peter John Fellner | M | 80 | 6 anni | |
| Jeffrey Farrow | M | 62 | 2 anni | |
| Suseelan R. Pookote | M | 70 | 19 anni | |
| Hubertus Schmoldt | M | 79 | - | |
| Søren Knud Carlsen | M | 72 |
Roche Innovation Center Copenhagen A/S
Roche Innovation Center Copenhagen A/S Pharmaceuticals: MajorHealth Technology Roche Innovation Center Copenhagen A/S discovers and develops drugs for the treatment of oncology, metabolic diseases, and infectious diseases. The firm manufactures a pipeline of drug candidates that act selectively on disease-related ribonucleic acid to provide patients with novel treatments for both rare and common diseases. It produces pre-clinical and clinical assets for the treatment of a range of diseases including oncology, metabolic diseases, and infectious diseases. The company was founded by Matts Lundwall and Mikael Ørum on January 1, 1998 and is headquartered in Horsholm, Denmark. | - |
| Colin Bond | M | 64 | 6 anni | |
| Terry Conrad | M | - | 3 anni | |
| Douglas Liu | M | 62 | 9 anni | |
| Kevin B. Bacon | M | 59 | 5 anni | |
| Colin Foster | M | 61 | 10 anni | |
| Vikram Lamba | M | 58 | 8 anni | |
| Edwin de Graaf | M | - |
Roche Innovation Center Copenhagen A/S
Roche Innovation Center Copenhagen A/S Pharmaceuticals: MajorHealth Technology Roche Innovation Center Copenhagen A/S discovers and develops drugs for the treatment of oncology, metabolic diseases, and infectious diseases. The firm manufactures a pipeline of drug candidates that act selectively on disease-related ribonucleic acid to provide patients with novel treatments for both rare and common diseases. It produces pre-clinical and clinical assets for the treatment of a range of diseases including oncology, metabolic diseases, and infectious diseases. The company was founded by Matts Lundwall and Mikael Ørum on January 1, 1998 and is headquartered in Horsholm, Denmark. | - |
| Mary C. Tanner | F | 73 | 9 anni | |
| Beat Christoph Krähenmann | M | 66 |
Roche Innovation Center Copenhagen A/S
Roche Innovation Center Copenhagen A/S Pharmaceuticals: MajorHealth Technology Roche Innovation Center Copenhagen A/S discovers and develops drugs for the treatment of oncology, metabolic diseases, and infectious diseases. The firm manufactures a pipeline of drug candidates that act selectively on disease-related ribonucleic acid to provide patients with novel treatments for both rare and common diseases. It produces pre-clinical and clinical assets for the treatment of a range of diseases including oncology, metabolic diseases, and infectious diseases. The company was founded by Matts Lundwall and Mikael Ørum on January 1, 1998 and is headquartered in Horsholm, Denmark. | - |
| John-Edward Butler-Ransohoff | M | - | 10 anni |
Statistiche
| Paese | Relazioni | % del totale |
|---|---|---|
| Germania | 69 | 88.46% |
| Danimarca | 11 | 14.10% |
Età delle relazioni
Attive
Scorse
Uomo
Donna
Amministratori
Dirigenti
Provenienza delle relazioni
- Borsa valori
- Insiders
- Walter Wenninger
- Contatti personali
